NGS in Gallbladder Cancer and Response to Treatment

Condition(s) studied

Investigational drug(s) / intervention(s)

Next generation sequencing: NGS is carried out on DNA isolated from paraffin embedded tissue

Study summary

Evidence suggests distinct models of molecular and pathologic progression, and a growing body of genetics data points to a heterogeneous collection of underlying mutations in key oncogenes and tumor suppressor genes. Although tumor genetics have been used to tailor individual treatment regimens and guide clinical decision making in other cancers, these principles have not been applied in gallbladder malignancy. Recent clinical trials with targeted therapies seem promising, although the relationships between subsets of patients with positive responses to therapy and tumor genetics remain unexplored.

Eligibility

Primary outcome measure(s)

• Response to treatment — 1 year
  Response to treatment in terms of chemotherapy
• Overall Survival — 5 year
  Survival of patients from the date of diagnosis to closure of study or death which ever is earlier

Trial sites (1)

More Banaras Hindu University trials in India